list of all glp-1 agonists America's Poison Centers Patents and regulatory exclusivities on

By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity

A study published in The Lancet in June 2023 reveals that over half a billion people globally are living with diabetes, impacting individuals of all ages and genders in every country

Other important safety information Wegovy is FDA approved to treat weight loss in adults with a BMI of 30 or greater

Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared

Signs of gallbladder problems, including right upper abdominal pain, jaundice, or clay-colored stools, warrant urgent assessment, as these medications can increase gallstone risk, particularly during rapid weight loss

Patients typically begin with a low dose usually 0.25 mg of semaglutide and increase the dosage every four weeks